Daiichi-Sankyo Becomes Newest IFPMA Member Company

Main Category: Pharma Industry / Biotech Industry
Article Date: 18 Jun 2008 - 6:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:not yet rated

Healthcare Prof:not yet rated


The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) is pleased to welcome Daiichi-Sankyo Company Limited as its newest member company.

IFPMA Director General Alicia Greenidge said: "We are very delighted to welcome Daiichi-Sankyo to IFPMA. This development will further enhance IFPMA's membership and Daiichi-Sankyo's vision as a truly global pharmaceutical innovator."

Daiichi-Sankyo, one of the largest pharmaceutical companies in Japan, was formed in September 2005, from the merger of Daiichi Pharmaceutical Co., Ltd. and Sankyo Co., Ltd. Its headquarters are in Chuo-ku, Tokyo, and it has subsidiary companies in developed markets, such as the USA and across the European Union, and also in emerging economies such as Brazil, China, Thailand and Venezuela.

Daiichi-Sankyo is a leader in the field of cardiovascular medicines, with various products for the treatment of hypertension, hyperlipidemia (excess cholesterol and other lipids) and diabetes, as well as for cardiovascular events such as heart failure, arrhythmia and heart attack. The company's corporate mission, "to contribute to the enrichment of quality of life around the world through the creation and provision of first in-class and best-in-class drugs," underlines its commitment to innovation, and its pipeline includes candidate medicines for blood clotting, cancer, diabetes and hypertension.

Daiichi-Sankyo has recently announced that it will take a majority stake in India's largest pharmaceutical company, Ranbaxy Laboratories, which is both a growing force in pharmaceutical R&D, and a leading manufacturer of generic medicines. Daiichi-Sankyo also has a consumer health division, which only operates in Japan, producing and marketing products for self-medication and skin care, as well as functional foods.

For more information on Daiichi-Sankyo, please go to http://www.daiichisankyo.com

About the IFPMA

The International Federation of Pharmaceutical Manufacturers & Associations is a non-profit, non-governmental organisation representing national industry associations and companies from both developed and developing countries. Member companies of the IFPMA are research-based pharmaceutical, biotech and vaccine companies.

International Federation of Pharmaceutical Manufacturers & Associations

Article adapted by Medical News Today from original press release.
Visit our pharma industry / biotech industry section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
International Federation of Pharmaceutical Manufac. "Daiichi-Sankyo Becomes Newest IFPMA Member Company." Medical News Today. MediLexicon, Intl., 18 Jun. 2008. Web.
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/111769.php>

APA
International Federation of Pharmaceutical Manufac. (2008, June 18). "Daiichi-Sankyo Becomes Newest IFPMA Member Company." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/111769.php.

Please note: If no author information is provided, the source is cited instead.


Pharma Industry / Biotech Industry

Most Popular Articles



Follow Our Pharma Industry News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Pharma Industry / Biotech Industry Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »